Richard J Wallace1, Barbara A Brown-Elliott2, Steven McNulty3, Julie V Philley4, Jessica Killingley3, Rebecca W Wilson5, Deanna S York3, Sara Shepherd5, David E Griffith6. 1. Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX; Department of Microbiology, University of Texas Health Science Center at Tyler, Tyler, TX; Department of Pathology, University of Texas Health Science Center at Tyler, Tyler, TX. 2. Department of Microbiology, University of Texas Health Science Center at Tyler, Tyler, TX; Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX. 3. Department of Microbiology, University of Texas Health Science Center at Tyler, Tyler, TX. 4. Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX. 5. Department of Pathology, University of Texas Health Science Center at Tyler, Tyler, TX. 6. Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX. Electronic address: david.griffith@uthct.edu.
Abstract
BACKGROUND: There is no large study validating the appropriateness of current treatment guidelines for Mycobacterium avium complex (MAC) lung disease. This is a retrospective single-center review evaluating the efficacy of macrolide/azalide-containing regimens for nodular/bronchiectatic (NB) MAC lung disease. METHODS: Patients were treated according to contemporary guidelines with evaluation of microbiologic responses. Macrolide susceptibility of MAC isolates was done at initiation of therapy, 6 to 12 months during therapy, and on the first microbiologic recurrence isolate. Microbiologic recurrence isolates also underwent genotyping for comparison with the original isolates. RESULTS: One hundred eighty patients completed > 12 months of macrolide/azalide multidrug therapy. Sputum conversion to culture negative occurred in 154 of 180 patients (86%). There were no differences in response between clarithromycin or azithromycin regimens. Treatment regimen modification occurred more frequently with daily (24 of 30 [80%]) vs intermittent (2 of 180 [1%]) therapy (P = .0001). No patient developed macrolide resistance during treatment. Microbiologic recurrences during therapy occurred in 14% of patients: 73% with reinfection MAC isolates, 27% with true relapse isolates (P = .03). Overall, treatment success (ie, sputum conversion without true microbiologic relapse) was achieved in 84% of patients. Microbiologic recurrences occurred in 74 of 155 patients (48%) after completion of therapy: 75% reinfection isolates, 25% true relapse isolates. CONCLUSIONS: Current guidelines for macrolide/azalide-based therapies for NB MAC lung disease result in favorable microbiologic outcomes for most patients without promotion of macrolide resistance. Intermittent therapy is effective and significantly better tolerated than daily therapy. Microbiologic recurrences during or after therapy are common and most often due to reinfection MAC genotypes.
BACKGROUND: There is no large study validating the appropriateness of current treatment guidelines for Mycobacterium avium complex (MAC) lung disease. This is a retrospective single-center review evaluating the efficacy of macrolide/azalide-containing regimens for nodular/bronchiectatic (NB) MAC lung disease. METHODS:Patients were treated according to contemporary guidelines with evaluation of microbiologic responses. Macrolide susceptibility of MAC isolates was done at initiation of therapy, 6 to 12 months during therapy, and on the first microbiologic recurrence isolate. Microbiologic recurrence isolates also underwent genotyping for comparison with the original isolates. RESULTS: One hundred eighty patients completed > 12 months of macrolide/azalide multidrug therapy. Sputum conversion to culture negative occurred in 154 of 180 patients (86%). There were no differences in response between clarithromycin or azithromycin regimens. Treatment regimen modification occurred more frequently with daily (24 of 30 [80%]) vs intermittent (2 of 180 [1%]) therapy (P = .0001). No patient developed macrolide resistance during treatment. Microbiologic recurrences during therapy occurred in 14% of patients: 73% with reinfection MAC isolates, 27% with true relapse isolates (P = .03). Overall, treatment success (ie, sputum conversion without true microbiologic relapse) was achieved in 84% of patients. Microbiologic recurrences occurred in 74 of 155 patients (48%) after completion of therapy: 75% reinfection isolates, 25% true relapse isolates. CONCLUSIONS: Current guidelines for macrolide/azalide-based therapies for NB MAC lung disease result in favorable microbiologic outcomes for most patients without promotion of macrolide resistance. Intermittent therapy is effective and significantly better tolerated than daily therapy. Microbiologic recurrences during or after therapy are common and most often due to reinfection MAC genotypes.
Authors: D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier Journal: Am J Respir Crit Care Med Date: 2010-06-10 Impact factor: 21.405
Authors: David E Griffith; Barbara A Brown-Elliott; Brett Langsjoen; Yansheng Zhang; Xi Pan; William Girard; Kenwyn Nelson; James Caccitolo; Julio Alvarez; Sara Shepherd; Rebecca Wilson; Edward A Graviss; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2006-07-20 Impact factor: 21.405
Authors: Richard D Kim; David E Greenberg; Mary E Ehrmantraut; Shireen V Guide; Li Ding; Yvonne Shea; Margaret R Brown; Milica Chernick; Wendy K Steagall; Connie G Glasgow; JingPing Lin; Clara Jolley; Lynn Sorbara; Mark Raffeld; Suvimol Hill; Nilo Avila; Vandana Sachdev; Lisa A Barnhart; Victoria L Anderson; Reginald Claypool; Dianne M Hilligoss; Mary Garofalo; Alan Fitzgerald; Sandra Anaya-O'Brien; Dirk Darnell; Rosamma DeCastro; Heather M Menning; Stacy M Ricklefs; Stephen F Porcella; Kenneth N Olivier; Joel Moss; Steven M Holland Journal: Am J Respir Crit Care Med Date: 2008-08-14 Impact factor: 21.405
Authors: R E Chaisson; C A Benson; M P Dube; L B Heifets; J A Korvick; S Elkin; T Smith; J C Craft; F R Sattler Journal: Ann Intern Med Date: 1994-12-15 Impact factor: 25.391
Authors: R J Wallace; Y Zhang; B A Brown; D Dawson; D T Murphy; R Wilson; D E Griffith Journal: Am J Respir Crit Care Med Date: 1998-10 Impact factor: 21.405
Authors: David E Griffith; Jennifer Adjemian; Barbara A Brown-Elliott; D Rebecca Prevots; Julie V Philley; Kenneth N Olivier; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2015-11-15 Impact factor: 21.405
Authors: Emily Henkle; Shannon A Novosad; Sean Shafer; Katrina Hedberg; Sarah A R Siegel; Jennifer Ku; Cara Varley; D Rebecca Prevots; Theodore K Marras; Kevin L Winthrop Journal: Ann Am Thorac Soc Date: 2017-07
Authors: Bruno Del Prato; Alfonso Maria Altieri; Biagio Carlucci; Pier Anselmo Mori; Roberto Parrella; Anna Stainer; Federica De Giacomi; Alberto Pesci; Paola Faverio Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2018-04-28 Impact factor: 0.670
Authors: Shelby Daniel-Wayman; Getahun Abate; Daniel L Barber; Luiz E Bermudez; Rhea N Coler; Michael H Cynamon; Charles L Daley; Rebecca M Davidson; Thomas Dick; R Andres Floto; Emily Henkle; Steven M Holland; Mary Jackson; Richard E Lee; Eric L Nuermberger; Kenneth N Olivier; Diane J Ordway; D Rebecca Prevots; James C Sacchettini; Max Salfinger; Christopher M Sassetti; Christine F Sizemore; Kevin L Winthrop; Adrian M Zelazny Journal: Am J Respir Crit Care Med Date: 2019-04-15 Impact factor: 21.405
Authors: David E Griffith; Jennifer Adjemian; Barbara A Brown-Elliott; Julie V Philley; D Rebecca Prevots; Christopher Gaston; Kenneth N Olivier; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2015-09-15 Impact factor: 21.405
Authors: David C Alexander; Ravikiran Vasireddy; Sruthi Vasireddy; Julie V Philley; Barbara A Brown-Elliott; Benjamin J Perry; David E Griffith; Jeana L Benwill; Andrew D S Cameron; Richard J Wallace Journal: J Clin Microbiol Date: 2016-12-07 Impact factor: 5.948